A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome.

Abstract

Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients.

• Authors: H Blaszyk, A Hartmann, J M Cunningham, D Schaid, L E Wold, J S Kovach, S S Sommer
• Journal: International journal of cancer (Int J Cancer) Vol. 89 Issue 1 Pg. 32-8 (Jan 20 2000) ISSN: 0020-7136 [Print] United States
• PMID: 10719728 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Topics

• Breast Neoplasms (genetics, mortality, pathology, therapy)
• Cohort Studies
• Follow-Up Studies
• Genes, p53
• Humans
• Immunohistochemistry
• Mutation
• Prognosis
• Prospective Studies